John L. Ufheil, president and chief executive of Celgene Corp.,was named chairman. Edmund T. Pratt Jr., chairman emeritusof Pfizer Inc., was named to the board. The Warren, N.J.,company (NASDAQ:CELG) is developing chiral chemicals andproprietary biotreatment systems to degrade hazardouswastes.
Henry L. Nordhoff has resigned as president, chief executiveand director of American Biogenetic Sciences Inc. to seek otheropportunities, the company said. Alfred J. Roach, chairman andfounder of the company, will serve temporarily as presidentand chief executive. The Notre Dame, Ind., company(NASDAQ:MABXA) is developing monoclonal antibody-basedproducts for cardiovascular disease.
Advanced Tissue Sciences Inc. of La Jolla, Calif., named BernardD. King senior vice president of research and clinicaldevelopment. He was vice president of medical and regulatoryaffairs worldwide for Convatec, Bristol-Meyers Squibb.Advanced Tissue Sciences (NASDAQ:ATISA) is a tissueengineering company.
ImClone Systems Inc. of New York named John A. Gilly vicepresident of product and process development. He was directorof product development at Connaught Laboratories Inc.ImClone (NASDAQ:IMCL) is developing products to treatselected cancers, disorders of the blood and immune system,and inflammatory diseases.
Sibia Inc. named Stanley T. Crooke, chairman and chiefexecutive of Isis Pharmaceuticals Inc., to its board. La Jolla,Calif.-based Sibia is developing diagnostic and therapeuticproducts for neurodegenerative conditions.
John H. Fried was named a director of Corvas International Inc.He was president of Syntex Corp.'s research division until hisretirement in March. San Diego-based Corvas (NASDAQ:CVAS)develops cardiovascular therapeutics.
Cel-Sci Corp. named F. Donald Hudson and Edwin A. Shallowayto its board. Hudson is founder or co-founder of IntegratedGenetics Inc., Organogenesis Inc. and TSI Corp. Shalloway is asenior partner and co-founder of the patent law firm ofSherman & Shalloway. Cel-Sci (NASDAQ:CELI) of Alexandria,Va., is focused on combination therapy for the treatment ofcancers and immunodeficiencies.George W. Ebright, Cytogen Corp. CEO and chairman of theboard, was elected to the board of directors of Univax BiologicsInc. The Rockville, Md., company (NASDAQ:UNVX) developsimmunotherapeutics for the prevention and treatment ofserious infectious diseases and conditions.
Yamanouchi Pharmaceutical Corp. executives Toichi Takenakaand Takao Miyamoto have been named to the board of RobertsPharmaceutical Corp. Takenaka is deputy director of centralresearch laboratories and director of medical researchlaboratories, and Miyamoto is director of YamanouchiInternational Division's Europe and Americas department.Roberts (NASDAQ:RPCX) of Eatontown, N.J., acquires, developsand markets human pharmaceuticals.
(c) 1997 American Health Consultants. All rights reserved.